Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures

Key messages for clinical practice

Grigorios I. Leontiadis, Frances Tse, Colin Howden

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Should we interrupt antiplatelet therapy (acetylsalicylic acid [ASA] alone or in combination with Clopidogrel) in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal (GI) procedures? The relevant evidence was critically appraised in a recent White Paper from the American College of Gastroenterology and the American College of Cardiology. Clinicians need to qualify and compare 2 competing risks: the increased risk of bleeding if antiplatelet therapy is maintained during the endoscopic GI procedure, vs. the increased risk of cardiovascular (CV) thrombosis if antiplatelet therapy is interrupted or modified in the periprocedural period. ASA treatment may be continued for all endoscopic GI procedures, provided that there is no pre-existing bleeding disorder. Clopidogrel administration could be maintained for low-risk endoscopic GI procedures, such as diagnostic endoscopy of the upper or lower GI tract with or without biopsies. For patients on Clopidogrel undergoing high-risk endoscopic GI procedures, such as polypectomy or sphincterotomy, the individualized risk of CV complications from Clopidogrel discontinuation should be assessed. During the first month following bare-metal stent implantation or the first 6 (possibly 12) months following drug-eluting stent placement the CV risk is particularly high, therefore elective high-risk endoscopic GI procedures should be deferred accordingly. In all other clinical situations requiring Clopidogrel treatment, the risk of CV events is lower than above. Therefore, Clopidogrel treatment could be interrupted for 7 to 10 days before the procedure (and restarted as soon as possible after the procedure), provided that ASA treatment is maintained. Copyright by Medycyna Praktyczna, 2010.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalPolskie Archiwum Medycyny Wewnetrznej
Volume120
Issue number4
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

clopidogrel
Coronary Artery Disease
Aspirin
Therapeutics
Lower Gastrointestinal Tract
Hemorrhage
Preexisting Condition Coverage
Upper Gastrointestinal Tract
Drug-Eluting Stents
Endoscopy
Stents
Thrombosis
Metals

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{4e9fc0197188412f9b97e7a93b206204,
title = "Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures: Key messages for clinical practice",
abstract = "Should we interrupt antiplatelet therapy (acetylsalicylic acid [ASA] alone or in combination with Clopidogrel) in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal (GI) procedures? The relevant evidence was critically appraised in a recent White Paper from the American College of Gastroenterology and the American College of Cardiology. Clinicians need to qualify and compare 2 competing risks: the increased risk of bleeding if antiplatelet therapy is maintained during the endoscopic GI procedure, vs. the increased risk of cardiovascular (CV) thrombosis if antiplatelet therapy is interrupted or modified in the periprocedural period. ASA treatment may be continued for all endoscopic GI procedures, provided that there is no pre-existing bleeding disorder. Clopidogrel administration could be maintained for low-risk endoscopic GI procedures, such as diagnostic endoscopy of the upper or lower GI tract with or without biopsies. For patients on Clopidogrel undergoing high-risk endoscopic GI procedures, such as polypectomy or sphincterotomy, the individualized risk of CV complications from Clopidogrel discontinuation should be assessed. During the first month following bare-metal stent implantation or the first 6 (possibly 12) months following drug-eluting stent placement the CV risk is particularly high, therefore elective high-risk endoscopic GI procedures should be deferred accordingly. In all other clinical situations requiring Clopidogrel treatment, the risk of CV events is lower than above. Therefore, Clopidogrel treatment could be interrupted for 7 to 10 days before the procedure (and restarted as soon as possible after the procedure), provided that ASA treatment is maintained. Copyright by Medycyna Praktyczna, 2010.",
author = "Leontiadis, {Grigorios I.} and Frances Tse and Colin Howden",
year = "2010",
month = "4",
day = "1",
language = "English (US)",
volume = "120",
pages = "143--147",
journal = "Polish Archives of Internal Medicine",
issn = "0032-3772",
publisher = "Medycyna Praktyczna",
number = "4",

}

TY - JOUR

T1 - Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures

T2 - Key messages for clinical practice

AU - Leontiadis, Grigorios I.

AU - Tse, Frances

AU - Howden, Colin

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Should we interrupt antiplatelet therapy (acetylsalicylic acid [ASA] alone or in combination with Clopidogrel) in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal (GI) procedures? The relevant evidence was critically appraised in a recent White Paper from the American College of Gastroenterology and the American College of Cardiology. Clinicians need to qualify and compare 2 competing risks: the increased risk of bleeding if antiplatelet therapy is maintained during the endoscopic GI procedure, vs. the increased risk of cardiovascular (CV) thrombosis if antiplatelet therapy is interrupted or modified in the periprocedural period. ASA treatment may be continued for all endoscopic GI procedures, provided that there is no pre-existing bleeding disorder. Clopidogrel administration could be maintained for low-risk endoscopic GI procedures, such as diagnostic endoscopy of the upper or lower GI tract with or without biopsies. For patients on Clopidogrel undergoing high-risk endoscopic GI procedures, such as polypectomy or sphincterotomy, the individualized risk of CV complications from Clopidogrel discontinuation should be assessed. During the first month following bare-metal stent implantation or the first 6 (possibly 12) months following drug-eluting stent placement the CV risk is particularly high, therefore elective high-risk endoscopic GI procedures should be deferred accordingly. In all other clinical situations requiring Clopidogrel treatment, the risk of CV events is lower than above. Therefore, Clopidogrel treatment could be interrupted for 7 to 10 days before the procedure (and restarted as soon as possible after the procedure), provided that ASA treatment is maintained. Copyright by Medycyna Praktyczna, 2010.

AB - Should we interrupt antiplatelet therapy (acetylsalicylic acid [ASA] alone or in combination with Clopidogrel) in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal (GI) procedures? The relevant evidence was critically appraised in a recent White Paper from the American College of Gastroenterology and the American College of Cardiology. Clinicians need to qualify and compare 2 competing risks: the increased risk of bleeding if antiplatelet therapy is maintained during the endoscopic GI procedure, vs. the increased risk of cardiovascular (CV) thrombosis if antiplatelet therapy is interrupted or modified in the periprocedural period. ASA treatment may be continued for all endoscopic GI procedures, provided that there is no pre-existing bleeding disorder. Clopidogrel administration could be maintained for low-risk endoscopic GI procedures, such as diagnostic endoscopy of the upper or lower GI tract with or without biopsies. For patients on Clopidogrel undergoing high-risk endoscopic GI procedures, such as polypectomy or sphincterotomy, the individualized risk of CV complications from Clopidogrel discontinuation should be assessed. During the first month following bare-metal stent implantation or the first 6 (possibly 12) months following drug-eluting stent placement the CV risk is particularly high, therefore elective high-risk endoscopic GI procedures should be deferred accordingly. In all other clinical situations requiring Clopidogrel treatment, the risk of CV events is lower than above. Therefore, Clopidogrel treatment could be interrupted for 7 to 10 days before the procedure (and restarted as soon as possible after the procedure), provided that ASA treatment is maintained. Copyright by Medycyna Praktyczna, 2010.

UR - http://www.scopus.com/inward/record.url?scp=77952822604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952822604&partnerID=8YFLogxK

M3 - Review article

VL - 120

SP - 143

EP - 147

JO - Polish Archives of Internal Medicine

JF - Polish Archives of Internal Medicine

SN - 0032-3772

IS - 4

ER -